C G Roehrborn
Overview
Explore the profile of C G Roehrborn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
130
Citations
2274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singla N, Walker J, Woldu S, Passoni N, de la Fuente K, Roehrborn C
Prostate Cancer Prostatic Dis
. 2017 Jan;
20(2):216-220.
PMID: 28117384
Background: We sought to determine whether formalin disinfection of prostate biopsy needles between cores reduces post-biopsy urinary tract infections (UTIs). Methods: We reviewed a single-surgeon experience of transrectal prostate biopsies...
2.
Egan K, Miner M, Suh M, McVary K, Ni X, Roehrborn C, et al.
Andrology
. 2015 Oct;
3(6):1165-72.
PMID: 26452447
Little is known about how total testosterone and estradiol-17β influence lower urinary tract symptoms (LUTS) in men with benign prostatic hypertrophy (BPH). We analyzed data from a subset of men...
3.
Roehrborn C, Spann M, Myers S, Serviss C, Hu L, Jin Y
Prostate Cancer Prostatic Dis
. 2014 Oct;
18(1):43-8.
PMID: 25348255
Background: To assess the efficacy and safety of LY500307, a selective estrogen receptor beta agonist, on lower urinary tract symptoms (LUTS) in patients with enlarged prostate secondary to BPH. Methods:...
4.
Rosen R, Yang M, Hall S, Roehrborn C
Urology
. 2014 Mar;
83(5):1041-50.
PMID: 24674118
Objective: To investigate the natural history of urologic symptom progression and remission by means of cluster analysis in a large, well-characterized cohort of men and women. Methods: Cluster analysis was...
5.
Kaplan S, Roehrborn C, Abrams P, Chapple C, Bavendam T, Guan Z
Int J Clin Pract
. 2011 Jan;
65(4):487-507.
PMID: 21210910
Despite potential benefits, primary care clinicians may avoid using antimuscarinics in men with overactive bladder (OAB) symptoms because of safety concerns. To review the efficacy and safety of antimuscarinics, alone...
6.
Erickstad L, Reed G, Bhat D, Roehrborn C, Lotan Y
Prostate Cancer Prostatic Dis
. 2010 Dec;
14(1):85-9.
PMID: 21151199
One purported advantage of electronic medical records (EMRs) is to improve patient care. This study uses a search of EMR to identify patients at risk for prostate cancer who were...
7.
Roehrborn C, Kaplan S, Lepor H, Volinn W
Prostate Cancer Prostatic Dis
. 2010 Dec;
14(2):143-8.
PMID: 21135869
Data from phase 3 studies (NCT00224107, NCT00224120) of silodosin for treatment of BPH symptoms were analyzed to examine the relationship between treatment efficacy and occurrence of abnormal ejaculation. Men aged...
8.
Stokes M, Black L, Benedict A, Roehrborn C, Albertsen P
Prostate Cancer Prostatic Dis
. 2010 Mar;
13(3):278-84.
PMID: 20212521
Limited data are available concerning long-term prostate cancer (PCa)-related medical costs for use in assessing PCa prevention strategies. The aim of this study was to examine treatment, long-term survival, and...
9.
Becher E, Roehrborn C, Siami P, Gagnier R, Wilson T, Montorsi F
Prostate Cancer Prostatic Dis
. 2009 Nov;
12(4):369-74.
PMID: 19901936
This article reports the results of a post hoc analysis of the multicenter, randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) study, which aimed to investigate the effects of dutasteride...
10.
Roehrborn C, Albertsen P, Stokes M, Black L, Benedict A
Prostate Cancer Prostatic Dis
. 2009 May;
12(4):355-60.
PMID: 19468284
Pharmacologic therapies are currently being evaluated for the prevention of prostate cancer (PCa). As additional clinical data become available regarding their benefits and risks, an examination of their economic impact...